USG bought 30 million doses of the (name changed) Jynneos vaccine over the past 20 years, frozen in bulk. Where did they go?
Then the US government ordered 7 million more doses since 2020. But CDC keeps saying the supply is limited... Limited to whom, by whom?
From today's Wall Street Journal:
“Given the current limited
supply of vaccine, CDC recom-
mends temporarily changing
some behaviors that may in-
crease a person’s risk of being
exposed,” an agency spokes-
Why is it that the CDC can never tell us the truth?
Below is from a July 15, 2022 press release issued by the vaccine manufacturer:
U.S. Government Orders Another 2.5 Million Doses of Monkeypox Vaccines from Bavarian Nordic
Bavarian Nordic to supply an additional 2.5 million doses of JYNNEOS® vaccine, bringing deliveries in 2022 and 2023 to a total of nearly 7 million doses
Filling capacity is being expanded with a U.S. based contract manufacturer who will fill the vaccines using existing bulk vaccine from previous orders from BARDA
Tech transfer to the contract manufacturer and manufacturing planned for 2022
Company upgrades its financial guidance for 2022
COPENHAGEN, Denmark, July 15, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has ordered an additional 2.5 million doses of liquid-frozen JYNNEOS®, a non-replicating smallpox vaccine and the only FDA-approved vaccine against monkeypox.
The new order follows two previous orders from BARDA in June and July 2022 for 500,000 and 2.5 million doses respectively which, together with an order from BARDA in 2020 for 1.4 million doses, will bring the total deliveries in 2022 and 2023 to nearly 7 million doses.
This additional order will be filled at a U.S. based contract manufacturer using bulk vaccine already manufactured and invoiced under previous contracts with BARDA and currently stored at Bavarian Nordic. A tech transfer of the process to the contract manufacturer will begin immediately, with the aim to manufacture all doses under this contract in 2022.
Paul Chaplin, President and CEO of Bavarian Nordic said: “Expanding our manufacturing capabilities into the United States allows Bavarian Nordic to deliver more monkeypox vaccines to meet the immediate worldwide demand for JYNNEOS. This quick response to a serious health crisis is only possible because of the U.S. government’s diligent long-term planning for their national preparedness.”